Researchers discover a critical cellular “off” switch for the inflammatory immune response that causes asthma attacks
Working with human immune cells in the laboratory, Johns Hopkins researchers report they have identified a critical cellular “off” switch for the inflammatory immune response that contributes to lung-constricting asthma attacks. The switch, they say, is composed of regulatory proteins that control an immune signaling pathway in cells.
“Asthma patients are constantly firing through this pathway because those proteins are stuck in the ‘on’ position, without proper control by other proteins that shut down this reaction,” says Nicola Heller, Ph.D., assistant professor of anesthesiology and critical care medicine at the Johns Hopkins University School of Medicine.
Asthma has been correlated with an overabundance of one type of immune cell called M2 macrophages in the lungs. In a nonasthmatic person, the M2 macrophages activate to clean up inhaled allergens and foreign particles, and then deactivate when the irritant is broken down.
However, in people with asthma, the M2 cells and the chemical signals they emit linger and call in other cells that cause inflammation that can trigger an asthma attack with the classic symptoms of difficulty breathing, wheezing and shortness of breath. Over time, the lung is changed by secretions from the M2 cells, which cause the lung tissue to remodel itself, contributing to irreversible obstruction and poor lung function. “If you prevent these cells from becoming the M2 type, you can potentially stop the continued inflammation and long-term structural changes,” says Heller.
The new research, reported Nov. 25 in the Journal of Biological Chemistry, investigated the role of two proteins, GRB10 and p70S6K, in the control of the signaling pathway that activates M2 cells.
In their previous work, also published in the Journal of Biological Chemistry Sept. 23, Heller’s group found that the inflammatory pathway involving the two proteins begins with interleukin 4 (IL-4), an immune system chemical that passes through a protein named IRS-2 before activating the M2 cells. They found that other proteins that stop the action of IRS-2 were not present in human M2 cells from people with allergies compared to healthy people. This made IRS-2 more active and increased the formation of M2 cells in people with allergies.
In the new study, Heller’s lab delved deeper into the IRS-2 pathway. By analyzing chemical changes of the IRS-2 protein in immortalized cultures of human white blood cells, it determined that IRS-2 appeared in two different forms — “on,” which allows the signal to pass through, and “off,” which stops the signal from activating the cells into M2 macrophages. They began by observing which proteins became active in the presence of IL-4 in human white blood cells and add “stop” signals to IRS-2. The activity of two regulatory proteins, GRB10 and p70S6K, increased after IL-4 exposure compared to the same cells that were not exposed to IL-4.
In further test tube experiments, the researchers treated the immortalized white blood cells with both chemical and genetic blockers, called small interfering RNA (siRNA), designed to render either p70S6K or GRB10 nonfunctional. The researchers saw that decreased GRB10 and p70S6K activity resulted in more of the “on” form of IRS-2, meaning these proteins are responsible for turning off IRS-2 and thereby downstream M2 production.
“This confirmed for us that without properly functioning GRB10 and p70S6K, the cells could not turn off IRS-2 signaling and M2 production,” says Heller.
The research team, Heller says, has already begun experiments to further explore the implications of these results, which include looking at differences in this pathway between cells taken from allergic and healthy individuals, and testing the efficacy of an inhalable drug that mimics the function of GRB1 and p70S6K to shut off the development of M2 macrophages in the lungs of mice. “One of the advantages of working with lung macrophages is that they are one of the first cells that see anything that gets put in an inhaler,” says Heller. “So we hope to modulate their activity in this way.”
These findings also have implications for treatment of cancer and other disorders, such as obesity, in which M2 macrophage cells play a regulatory role in tumor growth and fat deposition.
Learn more: Turning off Asthma Attacks
Receive an email update when we add a new ASTHMA article.
The Latest on: Asthma
via Google News
The Latest on: Asthma
- Studies show wildfire smoke linked to spike in asthma, strokes and heart attackson September 8, 2020 at 6:29 pm
Smoke from the August Lightning Complex fires that ravaged California led to hazardous air quality levels across much of the state and sent plumes of smoke as far as 1,500 miles away in Kansas. As a ...
- Coronavirus: Man with chronic asthma 'forced' to wear mask on planeon September 8, 2020 at 5:29 pm
The man was carrying an exemption card - but it was rejected by the crew on his journey from Jersey to Gatwick. Face coverings on UK public transport are mandatory but some people are allowed not to ...
- Chronic asthma sufferer 'forced' to wear mask on planeon September 8, 2020 at 4:30 pm
A man with serious breathing issues says he was "ambushed" into wearing a face covering on a plane on his journey from Jersey to Gatwick. Footage shows an EasyJet pilot refusing to accept his ...
- First Trial of Gene-Targeted Asthma Rx in Kids Shows Promiseon September 8, 2020 at 1:48 pm
"These results are very promising because they show, for the first time, that it could be beneficial to test for certain genetic differences in children with asthma and select med ...
- Regeneron, Sanofi’s Dupixent Shows Sustained Asthma Benefits In 3-Yr Trialon September 8, 2020 at 5:27 am
Regeneron Pharmaceuticals (REGN) and Sanofi have announced new results from a Dupixent (dupilumab) Phase 3 open-label extension trial that showed the safety and efficacy profile observed in previous D ...
- Children with asthma could benefit from prescribing according to genetic differenceson September 8, 2020 at 1:56 am
Selecting treatments according to genetic differences could help children and teenagers with asthma, according to research presented at the European Respiratory Society International Congress.
- Sanofi/Regeneron Dupixent shows sustained benefit in asthma extension studyon September 8, 2020 at 1:00 am
Sanofi (NASDAQ:SNY) and Regeneron Pharmaceuticals (NASDAQ:REGN) announce new results from a Dupixent (dupilumab) Phase 3 open-label extension trial that showed the safety and efficacy profile observed ...
- AB Science to present results from its Phase 3 AB07015 study in severe asthma at the annual European Respiratory Society International Congresson September 8, 2020 at 12:32 am
Paris, 08 September 2020, 7.30amAB Science to present results from its Phase 3 AB07015 study in severe asthma at the annual European Respiratory Society International Congress Abstract selected for mo ...
- Regeneron/Sanofi Reveal Promising Long-term Data Of Dupixent In Moderate-to-severe Asthmaon September 8, 2020 at 12:00 am
Dupixent is already approved in the U.S. for use with other asthma medicines for the maintenance treatment of moderate-to-severe eosinophilic or oral steroid dependent asthma in patients aged 12 years ...
via Bing News